Stryker (SYK)

• Market cap: $143B
• 1 day: 0.85%
• 5 days: 0.07%
• 1 month: -3.52%
• 3 months: 0.94%
• 6 months: 3.68%
• Year to date: 4.33%
• 1 year: 6.62%
• 5 years: 160.92%
• 10 years: 300.63%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.

Employees: 53,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

187% more first-time investments, than exits

New positions opened: 255 | Existing positions closed: 89

18% more repeat investments, than reductions

Existing positions increased: 825 | Existing positions reduced: 701

6% more funds holding

Funds holding: 1,999 [Q3] → 2,122 (+123) [Q4]

2% less capital invested

Capital invested by funds: $110B [Q3] → $108B (-$1.66B) [Q4]

6% less call options, than puts

Call options by funds: $518M | Put options by funds: $550M

1.84% less ownership

Funds ownership: 79.99% [Q3] → 78.15% (-1.84%) [Q4]

4% less funds holding in top 10

Funds holding in top 10: 76 [Q3] → 73 (-3) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $413 10% upside
• Avg. target: $437 17% upside
• High target: $450 20% upside

10 analyst ratings

• positive: 8 80%
• neutral: 2 20%
• negative: 0 0%

Needham Mike Matson 47% 1-year accuracy 58 / 124 met price target	18% upside $442	Buy Reiterated	21 Mar 2025
Citigroup Joanne Wuensch 44% 1-year accuracy 23 / 52 met price target	20% upside $450	Buy Reinstated	26 Feb 2025
Barclays Matt Miksic 63% 1-year accuracy 26 / 41 met price target	18% upside $443	Overweight Maintained	10 Feb 2025
Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target	14% upside $427	Neutral Maintained	30 Jan 2025
Truist Securities Richard Newitter 49% 1-year accuracy 21 / 43 met price target	10% upside $413	Hold Maintained	30 Jan 2025